Vireo Growth (VREOF) Long-Term Debt Issuances (2021 - 2026)
Vireo Growth (VREOF) reported Long-Term Debt Issuances of $4.5 million for Q1 2026, up 400.0% on a YoY basis from $900000.0 in Q1 2025, and up 103.94% sequentially from -$114.2 million in Q4 2025.
Vireo Growth (VREOF) Long-Term Debt Issuances (2021 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 6 years of Long-Term Debt Issuances data on file, last reported at $4.5 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Debt Issuances rose 400.0% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (up 40.14% YoY), and the FY2025 full-year result was $10.0 million, up 1.48% from the prior year.
- Long-Term Debt Issuances advanced to $4.5 million in Q1 2026, from -$114.2 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $124.5 million in Q3 2025 to a low of -$114.2 million in Q4 2025.
- A 5-year average of $3.3 million and a median of $1.0 million in 2023 frame the typical range for Long-Term Debt Issuances.
- Peak annual rise in Long-Term Debt Issuances reached 345682.24% in 2025, while the deepest fall reached 9766.67% in 2025.
- Tracing VREOF's Long-Term Debt Issuances over 5 years: stood at $894937.0 in 2022, then increased by 11.74% to $1.0 million in 2023, then surged by 775.63% to $8.8 million in 2024, then slumped by 1404.45% to -$114.2 million in 2025, then jumped by 103.94% to $4.5 million in 2026.
- Business Quant data shows VREOF's Long-Term Debt Issuances at $4.5 million in Q1 2026, -$114.2 million in Q4 2025, and $124.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 4.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.50 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | -114.22 Mn |
| Dec 31, 2025 | -114.22 Mn |
| Sep 30, 2025 | 124.48 Mn |
| Sep 30, 2025 | 124.48 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | 900,000.00 |
| Mar 31, 2025 | 900,000.00 |
| Dec 31, 2024 | 8.76 Mn |
| Dec 31, 2024 | 8.76 Mn |
| Sep 30, 2024 | 36,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |